Soleno Therapeutics (SLNO) Invested Capital (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Invested Capital data on file, last reported at $495.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $495.8 million, up 113.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $495.8 million (up 113.47% YoY), and the FY2025 annual result was $500.1 million, up 69.47% from the prior year.
• Invested Capital fell to $495.8 million in Q1 2026 per SLNO's latest filing, from $500.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $500.1 million in Q4 2025 and troughed at $2.6 million in Q1 2023.
• A 5-year average of $189.1 million and a median of $157.5 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2024: Invested Capital tumbled 90.03% in 2023, then jumped 5333.35% in 2024.
• A 5-year view of Invested Capital shows it stood at $10.3 million in 2022, then surged by 1422.1% to $157.5 million in 2023, then surged by 87.37% to $295.1 million in 2024, then soared by 69.47% to $500.1 million in 2025, then dropped by 0.86% to $495.8 million in 2026.
• Business Quant data shows SLNO's Invested Capital at $495.8 million in Q1 2026, $500.1 million in Q4 2025, and $494.8 million in Q3 2025.